Efficacy and safety of ciprofibrate in hyperlipoproteinaemias

Atherosclerosis

Volumn 124, Issue SUPPL., 1996, Pages

  Turpin, Gérard ^a   Bruckert, Eric ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

Ciprofibrate; Pharmacokinetics; Safety; Type IIa hypercholesterolaemia; Type IIb combined hyperlipidaemia; Type IV hypertriglyceridaemia

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; CIPROFIBRATE; COUMARIN ANTICOAGULANT; HYDANTOIN DERIVATIVE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN; SIMVASTATIN;

BILE ACID METABOLISM; CHOLESTEROL BLOOD LEVEL; CONFERENCE PAPER; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPOPROTEINEMIA; HYPERTRIGLYCERIDEMIA; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0029758187     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/0021-9150(96)05861-3     Document Type: Conference Paper

References (29)

1. Betteridge DJ. Ciprofibrate: a profile. Postgrad Med J 1993;69(Suppl 1):S42.
2. Beyer KH, Stadter H. The metabolism of ciprofibrate. Arch Pharm 1982;315:1049.
3. Czejka M. Binding to serum protein fractions and red blood cell partition coefficient of ciprofibrate. Arch Pharm 1991;324:287.
4. Brown DF, Beyler A, Daudiss K. Effective therapy in type II hyperlipoproteinaemia with a new long acting drug ciprofibrate. Am J Cardiol 1979;43:409.
5. Cattin L, Da Col PG, Feruglio FS, Finazzo L, Rimondi S, Descovich GC, Manzato E, Zambon S, Crepaldi G, Siepi D, Mannarino E, Ventura A. Efficacy of ciprofibrate in primary type II and IV hyperlipidaemia: the Italian multicenter study. Clin Ther 1990;12:482.
6. Dairou F, Regy C. Ciprofibrate multicentric study in 6,812 hyperlipidaemic patients. Florence: 9th Int Symp Drugs Lipid Metab, 1986;62.
7. De Gennes JL, Truffert J, Dairou F. Evaluation of the serum lipid lowering effect and tolerance of ciprofibrate. Sem Hôp Paris 1985;61:2807.
8. Illingworth DR, Olsen GD, Cook SF, Sexton GJ, Wendel HA, Connor WE. Ciprofibrate in the therapy of type II hypercholesterolemia. A double-blind trial. Atherosclerosis 1982;44:211.
9. Oro L, Carlson LA, Olsson A, Poole PH. Long term efficacy and safety of ciprofibrate in patients with primary hyperlipidemia. Curr Ther Res 1992;51:750.
10. Rouffy J, Chanu B, Aubert I, Djian F. Effects of ciprofibrate on lipid, lipoprotein and apoprotein levels and Achilles tendon xanthoma diameters: on the basis of ten cases of severe hypercholesterolaemia with tendon xanthoma. Sem Hôp Paris 1988;64:2357.
11. Schifferdecker E, Rosak C, Schoffling K. Long term treatment with the lipid lowering agent ciprofibrate. Ann Int Med 1984;11:107.
12. Shepherd J, Griffin B, Caslake M, Gaw A, Packard C. The influence of fibrates on lipoprotein metabolism. Atherosclerosis Rev 1991;22:163.
13. Eisenberg S, Gavish D, Oschry Y, Fainaru M, Deckelbaum RJ. Abnormalities in very low, low- and high-density lipoproteins in hypertriglyceridaemia. J Clin Invest 1984;74:470.
14. Bruckert E, Dejager S, Chapman MJ. Ciprofibrate therapy normalises the atherogenic low density lipoprotein subspecies profile in combined hyperlipidemia. Atherosclerosis 1993;100:91.
15. Brown MS, Goldstein JL. A receptor-mediated pathway for cholesterol homeostasis. Science 1986;232:34.
16. Olsson A. Efficacy, long term tolerance and persistence of the effects of ciprofibrate. J Am Med Assoc 1987(Suppl):4.
17. Blane GF. Comparative toxicity and safety profile of fenofibrate and other fibric acid derivatives. Am J Med 1987;83:26.
18. Baglin A, Lasserre N, Prinseau J, Lebas M. Rhabdomyolysis under treatment with ciprofibrate during a nephrotic syndrome. Thérapie 1987;42:247.
19. Bourrier P, Subra JF, Chennebault JM, Speisser R, Laine P. Toxic myopathy due to hypolipidaemic agents. Thérapie 1990;45:360.
20. Angelin B, Einarsson K, Leijd B. Clofibrate treatment and bile cholesterol saturation: short-term and long-term effects and influence of combination with chenodeoxycholic acid. Eur J Clin Invest 1981;11:185.
21. Coronary Drug Project Research Group. Clofibrate and niacin in coronary heart disease. J Am Med Assoc 1975;231:360.
22. Angelin B, Einarsson K, Leijd B. Effect of ciprofibrate treatment on biliary lipids in patients with hyperlipoproteinaemia. Eur J Clin Invest 1984;14:73.
23. Arnold A, McAuliff JP, Powers LG, Philips DK, Beyler AL. The results of animal studies with ciprofibrate, a new orally effective hypolipidemic drug. Atherosclerosis 1979;32:155.
24. Petit D, Bonnefis MT, Rey C, Infante R. Effects of ciprofibrate and fenofibrate on liver lipids and lipoprotein synthesis in normo- and hyperlipidemic rats. Atherosclerosis 1988;74:215.
25. Ferry N, Bernard N, Pozet N, Gardes E, Cuisinaud G, Labeeuw M, Zech PY, Sassard J. The influence of renal insufficiency and haemodialysis on the kinetics of ciprofibrate. Br J Clin Pharmacol 1989;28:675.
26. Simpson IA, Lorimer AR, Walker ID, Davidson JF. Effect of ciprofibrate on platelet aggregation and fibrinolysis in patients with hypercholesterolaemia. Thromb Haemostas 1985;54:442.
27. Carvalho De Sousa J, Bruckert E, Giral P, Soria C, Chapman MJ, Truffert J, Dairou F, De Gennes JL, Caen JP. Coagulation factor VII and plasma triglycerides. Haemostasis 1989;19:125.
28. Juhan-Vague I, Vague P, Alessi MC, Badier C, Valadier J, Ailhaud MF, Atlan C. Relationships between plasma insulin triglyceride, body mass index, and plasminogen activator inhibitor 1. Diabète Métab 1987;13:331.
29. Yarnell JWG, Baker IA, Sweetman PM, Bainton D, O'Brien JR, Whitehead PJ, Elwood PC. Fibrinogen, viscosity and white blood cell count are major risk factors for ischaemic heart disease. Circulation 1991;83:836.